Neoantigen therapy

ScientificConcept

A personalized cancer treatment that exposes the immune system to synthetic proteins mirroring tumor mutations, triggering an immune response.


First Mentioned

8/29/2026, 5:26:47 AM

Last Updated

9/5/2026, 5:51:17 AM

Research Retrieved

9/5/2026, 5:51:17 AM

Summary

Neoantigen therapy, also known as individualized neoantigen therapy (INT), is an advanced precision immunotherapy approach in oncology that utilizes patient-specific tumor mutations to mount a targeted immune response against malignant cells. When cancer cells mutate, they produce unique abnormal proteins called neoantigens that are distinct from healthy tissue antigens. By sequencing a patient's tumor biopsy alongside healthy cells, researchers identify these tumor-specific antigens and design personalized treatments—such as mRNA cancer vaccines, TCR-engineered T cells, tumor-infiltrating lymphocyte (TIL) therapies, or dendritic cell vaccines—that train T cells to selectively target and eradicate cancer cells. Key developers include biotechnology companies like Moderna in collaboration with Merck. Despite strong therapeutic promise in clinical trials for cancers such as melanoma and glioblastoma, clinical adoption faces challenges including high development costs, regulatory pricing dynamics, and tumor heterogeneity.

Research Data
Extracted Attributes
  • Scientific Field

    Oncology / Cancer Immunotherapy / Precision Medicine

  • Primary Modalities

    Personalized mRNA cancer vaccines, TCR-T therapy, CAR-T cell therapy, Tumor-Infiltrating Lymphocyte (TIL) therapy, peptide vaccines, and dendritic cell vaccines

  • Mechanism of Action

    Identifies tumor-specific genetic mutations producing neoantigens to train the host immune system (particularly T cells) to recognize and destroy cancer cells without harming healthy tissue

  • Key Target Indications

    Melanoma, Glioblastoma, and other solid tumors with high mutational burdens

  • Reported Cost / Economics

    Discussed as reaching up to $500,000 per patient for individualized courses

  • Primary Limitations and Challenges

    Tumor heterogeneity, immune evasion mechanisms, complex individual manufacturing timelines, and high treatment costs

Timeline
  • Moderna outlines its investigational individualized neoantigen therapies (INTs) developed in collaboration with Merck to design custom mRNA treatments based on patient tumor sequencing. (Source: https://www.modernatx.com/media-center/all-media/blogs/individual.neoantigen-therapies)

    2023-06-05

Antigen

In immunology, an antigen (Ag) is a molecule, or portion thereof, that can bind to a specific antibody or T-cell receptor. The presence of antigens in the body may trigger an immune response. Antigens can be proteins, peptides (amino acid chains), polysaccharides (chains of simple sugars), lipids, or nucleic acids. Antigens exist on normal cells, cancer cells, parasites, viruses, fungi, and bacteria. Antigens are recognized by antigen receptors, including antibodies and T-cell receptors. Diverse antigen receptors are made by cells of the immune system so that each cell has a specificity for a single antigen. Upon exposure to an antigen, only the lymphocytes that recognize that antigen are activated and expanded, a process known as clonal selection. In most cases, antibodies are antigen-specific, meaning that an antibody can only react to and bind one specific antigen; in some instances, however, antibodies may cross-react to bind more than one antigen. The reaction between an antigen and an antibody is called the antigen-antibody reaction. Antigen can originate either from within the body ("self-protein" or "self antigens") or from the external environment ("non-self"). The immune system identifies and attacks "non-self" external antigens. Antibodies usually do not react with self-antigens due to negative selection of T cells in the thymus and B cells in the bone marrow. The diseases in which antibodies react with self antigens and damage the body's own cells are called autoimmune diseases. Vaccines are examples of antigens in an immunogenic form, which are intentionally administered to a recipient to induce the memory function of the adaptive immune system towards antigens of the pathogen invading that recipient. The vaccine for seasonal influenza is a common example.

Web Search Results
  • What is neoantigen-based therapy?

    ## Neoantigen-targeted T cell therapy Neoantigen-targeted T cell therapy is a type of T cell therapy in which T cells are collected from the patient – either from the blood or directly from a tumor sample. From these T cells, naturally occuring T cells that have T cell receptors (TCRs) that recognize neoantigens can be isolated. Then, in the lab, these cells can be strengthened and increased in numbers before being given back to the patient as a living drug. The T cells then continue to multiply within the patient, where they recognize neoantigens and kill cancer cells. [...] Both tumor-associated antigens and neoantigens can serve as good targets for immunotherapy, however, neoantigens may be the stronger choice. Neoantigens are more likely than tumor-associated antigens to trigger a strong immune response, as they are entirely unfamiliar to the body – like the proteins of a virus or bacteria are – and easily stand out as molecules that do not belong. Further, while tumor-associated antigens may be found at low levels elsewhere in the body, neoantigens are completely unique to the cancer cells, so targeting neoantigens for immunotherapy comes with a lower risk of accidentally harming healthy cells along the way. For these two reasons – triggering stronger immune responses and being present only in cancer cells – neoantigens have become a preferred target for [...] In other cases, researchers may use T cell receptor (TCR) engineering to force T cells to target neoantigens. For TCR engineering, T cells are collected from a patient’s blood and a gene is added to code for a T cell receptor that recognizes a neoantigen that is known to be present in the patient’s cancer. These TCR-engineered T cells can then be grown and multiplied in the lab to form a massive T cell army that can be delivered back to the patient. When the engineered T cells are delivered back into the patient, they hunt down and attack any cells containing the neoantigens, leading them directly to cancer cells. T cell receptor engineering is currently focused on shared neoantigens, though researchers hope to one day apply it to personal neoantigens.

  • Individualised Neoantigen Therapy (INT) - Melanoma Focus

    ## Individualised Neoantigen Therapy (INT) ### What is an Individualised Neoantigen Therapy (INT)? An individualised neoantigen therapy or INT uses a persons’ own melanoma cells to create a treatment that can help their body’s natural defence (immune system) to recognise, attack and kill their melanoma. This is known as a personalised cancer treatment because it identifies and adapts the specific characteristics of a person’s cancer to try to make an effective treatment for them. These treatments are personalised cancer vaccines. DNA ### How do INTs work? [...] Receiving an individualised neoantigen therapy involves several steps. First, a sample of a person’s melanoma is collected and analysed to identify genetic changes that can give rise to neoantigens that may be recognised by the immune system. The information from the analysis is then used to design and manufacture an individualised treatment specifically for that person. Once the treatment has been manufactured, it is given to the person as an injection. The exact process and timing can vary, depending on the INT being studied and the clinical trial. ### What are the potential benefits and side effects of INT?

  • Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation

    Neoantigen-based immunotherapy has emerged as a transformative approach in cancer treatment, offering precision medicine strategies that target tumor-specific antigens derived from genetic, transcriptomic, and proteomic alterations unique to cancer cells. These neoantigens serve as highly specific targets for personalized therapies, promising more effective and tailored treatments. The aim of this article is to explore the advances in neoantigen-based therapies, highlighting successful treatments such as vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), and chimeric antigen receptor T cells therapy (CAR-T), particularly in cancer types like glioblastoma (GBM). Advances in technologies such as next-generation sequencing, RNA-based [...] This article explores the transformative potential of neoantigen-based immunotherapy, a precision oncology approach that targets TSAs arising from genetic, transcriptomic, and proteomic alterations. It examines various therapeutic modalities, including neoantigen vaccines, tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor-engineered T cells therapy (TCR-T), and chimeric antigen receptor T cells therapy (CAR-T), all of which show promise in treating GBM. The article also highlights how advances in NGS, RNA-based platforms, and CRISPR gene-editing technologies have accelerated neoantigen discovery, facilitating the development of highly personalized treatments. However, clinical application remains challenging due to factors such as tumor heterogeneity, immune evasion, and [...] The principal neoantigen-based strategies include TCR-T therapy, CAR-T cell therapy, bispecific antibodies, neoantigen vaccines, TIL therapy, oncolytic virus therapies, cancer peptide vaccines, dendritic cell (DC) vaccines, and personalized multi-epitope vaccines [149)]. TCR-T therapy involves the genetic engineering of autologous T cells to express TCRs capable of recognizing neoantigens presented by MHC-I molecules on the tumor cell surface [150)]. CAR-T therapy modifies T cells to express synthetic antigen-binding receptors that can directly recognize tumor surface antigens without the need for MHC presentation, broadening their applicability to tumors with low MHC expression [151)]. Bispecific antibodies act as immune engagers by simultaneously binding TSAs and CD3 on T cells,

  • Individualized Neoantigen Therapies

    Cancer cells express abnormal proteins, or neoantigens, that are not usually seen in normal cells. These cancer proteins make up a patient’s cancer “fingerprint.” Individualized neoantigen therapies are designed with the goal of specifically matching one patient's unique cancer fingerprint. The goal of individualized neoantigen therapies is to train a patient's immune cells to recognize the cancer fingerprint proteins and launch an immune response against the cancer cells. Individualized neoantigen therapies are currently being studied in clinical trials. As of today, there are currently no FDA-approved individualized neoantigen therapies. How are Investigational mRNA Individualized Neoantigen Therapies Made? [...] The process to make our individualized neoantigen therapy starts in the clinic, where a study participant has their blood drawn and their tumor biopsied. Sequencing is then performed in a lab to compare data from the tumor biopsy sample and the study participant’s healthy blood cells, which are not mutated, to identify the unique genetic mutations of that individual’s cancer. [...] Blogs / Exploring One Medicine for One Patient... 05 June 2023 # Exploring One Medicine for One Patient: Individualized Neoantigen Therapies By Michelle Brown, VP, INT Oncology Each person’s cancer is different because cancer cells have genetic mutations that make them unique, which can make the cancer difficult to treat. That's why we, in collaboration with Merck, are researching mRNA medicines that are designed specifically for an individual patient. Individualized neoantigen therapies (INTs) are an innovative approach that tailor treatment to each patient's individual cancer.

  • Neoantigen-directed therapeutics in the clinic: where are we? - PMC

    of neoepitope variants . This could be explained by the selective pressure imposed by the ICI-activated immune system on the selected set of spontaneously recognized neoantigens. Broadening and diversifying the tumor-reactive T cell repertoire and increasing the number of infiltrating tumor-specific T cells through other forms of immunotherapy, such as cancer vaccination, is therefore a promising strategy to synergize with ICI therapy, particularly for patients with ‘cold’ tumors . Neoantigen-directed therapy in general is aimed at strengthening and broadening immune responses to specific neoantigens on the tumor surface so as to enable or enhance the recognition and elimination of cancer cells. Because the majority of neoantigens are unique to the individual tumor and are absent in [...] ## Abstract In the past decade, immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T cell therapy have brought immunotherapy to the forefront of cancer treatment; however, only subsets of patients benefit from current approaches. Neoantigen-driven therapeutics specifically redirect the immune system of the patient to enable or reinduce its ability to recognize and eliminate cancer cells. The tumor specificity of this strategy spares healthy and normal cells from being attacked. Consistent with this concept, initial clinical trials have demonstrated the feasibility, safety, and immunogenicity of neoantigen-directed personalized vaccines. We review neoantigen-driven therapy strategies as well as their promise and clinical successes to date.